Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pro-doxorubicin

            Therapeutic Area: Oncology Product Name: AVA6000

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Point Biopharma

            Deal Size: $17.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 07, 2021

            Details:

            Deal provides POINT with license to pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FAP activated doxorubicin prodrug

            Therapeutic Area: Oncology Product Name: AVA6000

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 23, 2020

            Details:

            The dose-escalation phase of the study, which will be carried out in 15-20 patients, is designed to evaluate the safety of AVA6000 in humans and establish the appropriate dosing levels for the dose expansion phase of the study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PLX4720,Talimogene laherparepvec,Antibodies

            Therapeutic Area: Oncology Product Name: PLX4720

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oracle Cancer Trust

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2020

            Details:

            The BRAF drug, called PLX4720, which targets this genetic mutation, was developed at the ICR, and produces significant results in both thyroid cancers and melanomas which carry the mutation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SOL-578

            Therapeutic Area: Oncology Product Name: SOL-578

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: PharmaEngine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 04, 2020

            Details:

            Under the terms of the Agreement, Sentinel Oncology will receive an exclusivity payment and PharmaEngine will obtain an option to receive the exclusive rights to develop and commercialize SOL-578 worldwide.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BT7480

            Therapeutic Area: Oncology Product Name: BT7480

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            New data presented at SITC demonstrate that treatment with BT7480 leads to significant modulation of the tumor microenvironment, including immune checkpoints. Finding supports potential dosing of BT7480 in combination with checkpoint inhibitors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KT-413

            Therapeutic Area: Oncology Product Name: KT-413

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            ABSTRACT “KTX-120, a Novel IRAKIMiD Degrader of IRAK4 and IMiD substrates shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX models,” presented by Duncan H. Walker, PhD, Vice President of Oncology at Kymera Therapeutics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): STC-15

            Therapeutic Area: Oncology Product Name: STC-15

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            STC-15 is an orally bioavailable, small molecule METTL3 inhibitor targeting an entirely new mechanism of action (modulation of RNA epigenetics) to treat acute myeloid leukaemia (AML) and other solid and haematological cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EPS 201

            Therapeutic Area: Oncology Product Name: EPS 201

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innovate UK

            Deal Size: $1.3 million Upfront Cash: Undisclosed

            Deal Type: Funding October 21, 2020

            Details:

            Epsilogen will collaborate with King’s College London (KCL) and use the funding from the grant to further develop the company’s novel cancer immunotherapeutic EPS 201.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BT7480

            Therapeutic Area: Oncology Product Name: BT7480

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            BT7480 is a novel, fully synthetic TICA targeting Nectin-4, agonizing CD137. EphA2/CD137 TICAs are comprised of Bicycles that target the tumor antigen EphA2, which is overexpressed in a range of solid tumor types and associated with poor outcomes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SDC-1802

            Therapeutic Area: Oncology Product Name: SDC-1802

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            The patent will protect the SDC-1802 molecule and pharmaceutical preparations thereof. Subject to certain formalities being completed, the Company expects that the patent will be granted within three months.

            PharmaCompass